Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06130254 · ClinicalTrials.gov registry record · Phase 1

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

A Phase 1 study of Advanced Solid Tumor and Non-small Cell Lung Cancers, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
52
Enrollment target
1
Study location

NCT06130254 is a Phase 1 study of Advanced Solid Tumor and Non-small Cell Lung Cancers that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 52 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06130254, a Phase 1 study of Advanced Solid Tumor and Non-small Cell Lung Cancers, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

Evaluate safety and tolerability, while establishing the recommended dose of the investigational drug combination of adagrasib and olaparib that can be given to participants with advanced solid tumor(s) with a KRAS G12C and/or KEAP1 mutation.

Conditions Studied

Advanced Solid Tumor Non-small Cell Lung Cancers

Interventions

  • DRUG Olaparib
  • DRUG Adagrasib

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2024-01-30
Est. Completion 2030-08-25
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06130254

The ClinicalTrials.gov registry entry for NCT06130254 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (73% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.

NCT06130254 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06130254 about?

NCT06130254 is a clinical study titled "Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers". Evaluate safety and tolerability, while establishing the recommended dose of the investigational drug combination of adagrasib and olaparib that can be given to participants with advanced solid tumor(s) with a KRAS G12C and/or KEAP1 mutation.

What is the current status of trial NCT06130254?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2024-01-30. Estimated completion is 2030-08-25.

What conditions does trial NCT06130254 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Non-small Cell Lung Cancers.

What interventions are being tested in trial NCT06130254?

The interventions under investigation include: Olaparib (DRUG), Adagrasib (DRUG).

Who is sponsoring clinical trial NCT06130254?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06130254 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Non-small Cell Lung Cancers

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.